Monopar Therapeutics Net Cash Flow 2018-2025 | MNPR

Monopar Therapeutics net cash flow from 2018 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.

Monopar Therapeutics Net Cash Flow 2018-2025 | MNPR

Monopar Therapeutics net cash flow from 2018 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$247.8B
Amgen (AMGN)$154.9B
Gilead Sciences (GILD)$140.2B
Vertex Pharmaceuticals (VRTX)$100.3B
Bristol Myers Squibb (BMY)$96B
GSK (GSK)$80.8B
CSL (CSLLY)$67.1B
Regeneron Pharmaceuticals (REGN)$61.5B
Alnylam Pharmaceuticals (ALNY)$58.5B
Argenex SE (ARGX)$43.6B
Insmed (INSM)$28.8B
BioNTech SE (BNTX)$24B
Royalty Pharma (RPRX)$21B
Biogen (BIIB)$19.4B
Incyte (INCY)$16.5B
Genmab (GNMSF)$16.5B
Genmab (GMAB)$16B
Illumina (ILMN)$15.4B
Ascendis Pharma (ASND)$11.9B
BioMarin Pharmaceutical (BMRN)$11.2B
Swedish Orphan Biovitrum (BIOVF)$10.9B
QIAGEN (QGEN)$10.3B
Exelixis (EXEL)$10.1B
Moderna (MRNA)$9.4B
Verona Pharma American Depositary Share (VRNA)$9.2B
Exact Sciences (EXAS)$9B
Bio-Techne Corp (TECH)$8.6B
Halozyme Therapeutics (HALO)$8.6B
Guardant Health (GH)$8.4B
Blueprint Medicines (BPMC)$8.3B